MedTrace Logo

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

NCT04376034 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2026-05-29

Study results available
· View outcomes & findings →

Summary

This is a prospective study, using plasma to help fight off infections of those suffering from COVID-19 in accordance with collection guidelines for plasma and FDA IND requirements. This study included up to 240 participants potentially receiving convalescent plasma.

NOTE: West Virginia does not have any entity with the required FDA registration/licensure or necessary equipment to collect convalescent plasma for transfusion. Therefore, the plasma donation portion of this study was not completed.

Conditions

  • COVID19
  • Coronavirus Infection
  • Coronavirus
  • Virus Diseases
  • RNA Virus Infections

Interventions

BIOLOGICAL

Convalescent Plasma

1 to 2 units given over 4-6 hours. A unit will consist of about 200mL for both pediatric and adult populations. An additional unit of plasma will be given every 3 days up to 8 units if patient was not improving or getting worse. All pediatric patients will receive 10 mL/kg (1 dose) if moderate with concern for rapid progression up to 1 Unit; 10 mL/kg up to 2 units if severe or critical.

Sponsors & Collaborators

  • West Virginia University

    lead OTHER

Principal Investigators

  • Brian Peppers, DO, PhD · WVU Medicine Children's

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
31 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-16
Primary Completion
2021-02-28
Completion
2021-04-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04376034 on ClinicalTrials.gov